PRO-C3 was not measured in our animal model, so we were unable to ascertain if there were any effects on this neoepitope biomarker; (2) in PCLS from patient donors with PF, nintedanib led to reductions in type III collagen formation and degradation, assessed by PRO-C3 and C3M levels in a concentration-dependent manner, with EC50 values for C3M and PRO-C3 at or slightly above the expected clinical exposure after standard dosing of 150 mg nintedanib twice daily in patients with IPF [26–28]. The gene discussed is C3; the disease is idiopathic interstitial pneumonia.